Authors

Latest:

Dr. Noy on Next Phase of a Trial With Devimistat in Relapsed/Refractory Burkitt Lymphoma

Ariela Noy, MD, discusses the next phase of a trial with devimistat in patients with relapsed/refractory Burkitt lymphoma.

Arielz Katz

Latest:

RET Inhibitor Tested in Multiple Tumor Types

Investigators are evaluating the potential of LOXO-292, an oral small molecule inhibitor of RET signaling, to improve outcomes in patients with RET fusion–positive non–small cell lung cancer, medullary thyroid cancer, and other tumors.

Arizona Oncology

Arjun Balar, MD

Latest:

Dr. Balar on Results of KEYNOTE-052 in Urothelial Cancer

Arjun Balar, MD, director, Genitourinary Medical Oncology Progam, NYU Langone Medical Center, discusses the results from the KEYNOTE-053 trial in cisplatin-ineligible advanced urothelial carcinoma.

Arjun Gupta, MD

Latest:

The Patient Is Ready, But the Insurance Is Not

To provide the best care for the patients in front of us, oncologists must once again go above and beyond as needed.

Arjun V. Balar, MD

Latest:

Dr. Balar on Next Steps of the KEYNOTE-057 Trial in NMIBC

Arjun V. Balar, MD, director, Genitourinary Medical Oncology Program, assistant professor, Department of Medicine, NYU Langone's Perlmutter Cancer Center, discusses the next steps for research regarding the phase II KEYNOTE-057 trial in nonmuscle–invasive bladder cancer (NMIBC).

Arjun V. Balar, MD, Laura

Arjun Vasant Balar, MD

Latest:

Molecularly Targeted Therapy and Immunotherapy: The Next Frontier in Metastatic Bladder Cancer

A major step toward improved tolerability of cisplatin-based therapy came in the early 2000s with the advent of the modern regimen of gemcitabine and cisplatin.

Arlene Chan, MD

Latest:

Dr. Chan on ExteNET Trial for HER2+ Breast Cancer

Arlene Chan, MD, director, Mount Hospital at Perth, discusses the ExteNET trial, which looked at neratinib as extended adjuvant therapy in patients with early-stage HER2-positive breast cancer.

Arlene O. Siefker-Radtke, MD

Latest:

Dr Siefker-Radtke on the Safety of Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

Arlene O. Siefker-Radtke, MD, discusses toxicities associated with enfortumab vedotin plus pembrolizumab in patients with bladder cancer.

Arlene O. Siefker-Radtke, MD, The University of Texas MD Anderson Cancer Center

Latest:

Tissue and Liquid Biopsies in Metastatic Urothelial Cancer

A discussion on current prognostic and predictive testing assays used to detect FGFR mutations in patients with metastatic urothelial cancer (mUC).

Arlene Sharpe, MD, PhD

Latest:

Dr. Arlene Sharpe on the Role of the PD-1 Pathway

Arlene Sharpe, MD, PhD, immunology faculty member, Harvard Medical School, discusses the biology of the PD-1 pathway.

Armin Ghobadi, MD

Latest:

Dr Ghobadi on the Efficacy and Safety of WU-CART-007 in R/R T-ALL and LBL

Armin Ghobadi, MD, discusses the efficacy and safety of WU-CART-007 in heavily pretreated patients with relapsed/refractory T-ALL and LBL.

Arndt Vogel, MD, Hannover Medical School

Latest:

Biomarkers to Guide HCC Treatment Decisions

Professionals who treat patients with hepatocellular carcinoma comment on the need for more research and biomarkers to fuel treatment decisions.

Arndt Vogel, MD

Arndt Vogel, MD, is a faculty member at the University of Toronto Institute of Medical Science, a scientist at the Toronto General Hospital Research Institute, and a medical oncologist at the UHN–Princess Margaret Cancer Centre

Latest:

European Approval of Zanidatamab Expands Treatment Options for HER2+ Biliary Tract Cancer: With Arndt Vogel, MD

Dr Vogel highlights the importance of the European Commission’s approval of zanidatamab for previously treated, metastatic HER2+ biliary tract cancer.

Arndt Vogel, MD, PhD, Hannover Medical School

Arndt Vogel, MD, PhD, Hanover Medical School

Arnold B. Etame, MD, PhD

Latest:

The Awake Craniotomy Presents Advantages in Resection of Eloquent Cortex Brain Tumors

Awake craniotomies are traditionally reserved for, but not limited to, tumors involving the primary motor and speech areas

Arnold Etame, MD, PhD

Latest:

Dr Etame on How Patient Socioeconomic Status Affects Cancer Care

Arnold Etame, MD, PhD, discusses the effects of a patient’s socioeconomic status on the cancer treatment options they receive.

Arnold M. Markoe, MD

Latest:

Therapeutic Ratio of Hypofractionation in Early Glottic Cancer: A Topic Worth Revisiting?

A retrospective experience suggests that early glottic cancer treated with HRT results in a higher incidence of acute toxicity without improved control compared to CRT delivered in an appropriate OTT.